Analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to report $469.25 million in sales for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for Jazz Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $464.60 million and the highest estimate coming in at $472.21 million. Jazz Pharmaceuticals reported sales of $394.39 million during the same quarter last year, which suggests a positive year-over-year growth rate of 19%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 14th.

On average, analysts expect that Jazz Pharmaceuticals will report full year sales of $1.90 billion for the current fiscal year, with estimates ranging from $1.88 billion to $1.92 billion. For the next fiscal year, analysts anticipate that the company will report sales of $2.17 billion per share, with estimates ranging from $2.07 billion to $2.26 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.73 by ($0.15). The company had revenue of $436.40 million for the quarter, compared to analysts’ expectations of $440.91 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%.

JAZZ has been the topic of a number of recent analyst reports. Seaport Global Securities set a $175.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 6th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $201.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, March 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, April 30th. Bank of America increased their price target on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, February 20th. Finally, B. Riley increased their price target on shares of Jazz Pharmaceuticals from $206.00 to $211.00 and gave the stock a “buy” rating in a research note on Thursday, May 10th. Five investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $182.54.

Jazz Pharmaceuticals opened at $169.00 on Friday, MarketBeat.com reports. The company has a current ratio of 3.00, a quick ratio of 2.88 and a debt-to-equity ratio of 0.55. The company has a market cap of $9.93 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 0.85 and a beta of 0.97. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $169.25.

In related news, SVP Karen J. Wilson sold 3,899 shares of the firm’s stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $155.00, for a total transaction of $604,345.00. Following the completion of the sale, the senior vice president now directly owns 19,517 shares of the company’s stock, valued at approximately $3,025,135. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Paul Treacy sold 594 shares of the firm’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $141.47, for a total transaction of $84,033.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,825 shares of company stock valued at $2,467,865. Company insiders own 4.30% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Summit Trail Advisors LLC grew its holdings in Jazz Pharmaceuticals by 8,591.5% during the 1st quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock valued at $102,000 after purchasing an additional 100,950 shares in the last quarter. US Bancorp DE grew its holdings in Jazz Pharmaceuticals by 49.5% during the 4th quarter. US Bancorp DE now owns 1,087 shares of the specialty pharmaceutical company’s stock valued at $147,000 after purchasing an additional 360 shares in the last quarter. We Are One Seven LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $157,000. Financial Gravity Wealth Inc. acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $192,000. Finally, Brighton Jones LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $205,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.